Current Oncology Reports最新文献_第2页

Unveiling the Role of the Cellular Tumor Microenvironment and the Therapeutic Targets it Provides in Cutaneous T-Cell Lymphoma.

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-03-08 DOI: 10.1007/s11912-025-01646-6

Nikolaos A Chinas, Stella Kaliampou, Vasiliki Nikolaou

{"title":"Unveiling the Role of the Cellular Tumor Microenvironment and the Therapeutic Targets it Provides in Cutaneous T-Cell Lymphoma.","authors":"Nikolaos A Chinas, Stella Kaliampou, Vasiliki Nikolaou","doi":"10.1007/s11912-025-01646-6","DOIUrl":"https://doi.org/10.1007/s11912-025-01646-6","url":null,"abstract":"Purpose of review: Cutaneous T-Cell Lymphoma (CTCL) poses challenges both in diagnosis and prognosis. The purpose of this review is to address the role of profiling immune and non-immune cells in the tumor microenvironment (TME) as it provides information for better diagnosis, prognosis, biomarker discovery, and personalized treatment strategies.Recent findings: Recent evidence suggests that the progression of CTCL is closely linked to the Tumor Microenvironment (TME) which comprises various cell types including immune cells, stromal cells, blood vessels, and the extracellular matrix. Cell profiling within the TME demonstrates the perplexity of intracellular communication of the different cell fates and their mediators as the disease progresses. CTCL as a rare form of non-Hodgkin lymphoma often misdiagnosed due to its similarity to other skin conditions. It encompasses diseases like Mycosis fungoides (MF) and Sézary Syndrome (SS), with the latter being more severe. Advances in studying the TME have shown its pivotal role in CTCL progression, highlighting the need for comprehensive cell profiling to enhance diagnosis, prognosis, and treatment personalization.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiology of cancer in older adults: a systematic review of age-related differences in solid malignancies treatment.

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-15 DOI: 10.1007/s11912-025-01638-6

Esther Bastiaannet, Sophie Pilleron

{"title":"Epidemiology of cancer in older adults: a systematic review of age-related differences in solid malignancies treatment.","authors":"Esther Bastiaannet, Sophie Pilleron","doi":"10.1007/s11912-025-01638-6","DOIUrl":"10.1007/s11912-025-01638-6","url":null,"abstract":"Purpose of review: We examined the latest epidemiological research on age-related differences in cancer treatment and selected outcomes, among patients with cancer aged 60 and above in comparison to younger patients.Recent findings: Colorectal, pancreatic and lung cancers were studied most often. Most studies were conducted in Europe or the United States of America (USA) within single centers. For unselected patients, older patients receive less treatment, and their survival, regardless of the metric used (cancer-specific survival or overall survival), was poorer than that of middle-aged patients. Age-related differences in treatment and outcomes were more pronounced in patients aged over 80 years. However, among patients selected for treatment, complications, adverse events rates and survival probabilities were comparable between older and younger patients. Treatment differences, especially the omission of therapy, were often smaller for good prognosis cancer types. The likelihood of receiving treatment decreased as age increases, regardless of the cancer types, treatment, countries and setting. More research on treatment in older patients with cancer, especially the frailest and the oldest, is urgently needed as there is still a lack of data to tailor treatment.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"290-311"},"PeriodicalIF":4.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Impact of Diet and Nutrition on Prostate Cancer - Food for Thought?

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-15 DOI: 10.1007/s11912-025-01641-x

Rodrick Babakhanlou, Krisstina Gowin

引用次数: 0

Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma.

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-12 DOI: 10.1007/s11912-025-01639-5

Bhavesh Mohan Lal, Frits van Rhee, Samer Al Hadidi

{"title":"Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma.","authors":"Bhavesh Mohan Lal, Frits van Rhee, Samer Al Hadidi","doi":"10.1007/s11912-025-01639-5","DOIUrl":"10.1007/s11912-025-01639-5","url":null,"abstract":"Purpose of review: This review aims to address the subgroup of patients with newly diagnosed multiple myeloma (NDMM) who have high-risk multiple myeloma (HRMM) and continue to experience poor outcomes despite recent therapeutic advances. We will explore various clinical, biochemical, imaging, genetic, and dynamic features associated with high-risk status, along with the different risk stratification tools developed to identify HRMM patients.Recent findings: Although numerous parameters for defining HRMM have been proposed, a universally accepted definition remains absent. Studies have shown diverse treatment responses and varying outcomes in HRMM patients, prompting the development of tailored therapeutic approaches. Emerging evidence supports the need for refined definitions and more targeted strategies to improve HRMM management. HRMM patients represent an unmet need in NDMM treatment, and a standardized definition for HRMM is crucial for advancing research and clinical care. This review discusses current and future treatment options, the necessity for a consistent HRMM definition, and the importance of clinical trials focused on this high-risk group to bridge existing treatment gaps.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"258-277"},"PeriodicalIF":4.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastrointestinal Stromal Tumors. 胃肠道间质瘤

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-22 DOI: 10.1007/s11912-025-01636-8

Gal Strauss, Suzanne George

引用次数: 0

Paediatric Renal Tumors: A State-of-the-Art Review.

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-07 DOI: 10.1007/s11912-025-01644-8

Cecilia Salzillo, Gerardo Cazzato, Gabriella Serio, Andrea Marzullo

{"title":"Paediatric Renal Tumors: A State-of-the-Art Review.","authors":"Cecilia Salzillo, Gerardo Cazzato, Gabriella Serio, Andrea Marzullo","doi":"10.1007/s11912-025-01644-8","DOIUrl":"10.1007/s11912-025-01644-8","url":null,"abstract":"Purpose of review: Pediatric renal tumors comprise a wide range of conditions, both malignant and benign, that affect children and require a multidisciplinary approach for optimal diagnosis and treatment. This review offers an in-depth analysis of the epidemiology, diagnosis, treatment options, outcomes, and survival of major pediatric renal tumors.Recent findings: Wilms tumor, or nephroblastoma, is the most common form of renal tumor in children, characterized by growth from primitive renal cells. Standard treatment involves a combination of surgery, chemotherapy and, in some cases, radiation therapy, with the aim of removing the tumor, preventing recurrence and maximizing the chances of long-term recovery. Less common pediatric renal tumors, such as renal clear cell sarcoma, renal cell carcinoma, mesoblastic nephroma, and malignant rhabdoid tumor, require similarly careful and individualized management. Therapeutic strategies, which depend on the characteristics of the tumor, the stage of the disease and the individual response to therapy, may include surgery, chemotherapy, radiotherapy and, in some cases, molecular targeted therapies, immunotherapies and genetic and epigenetic therapies. The management of pediatric kidney tumors requires the involvement of a multidisciplinary team of specialists to ensure accurate evaluation, optimal treatments and long-term follow-up. The aim is to maximize the prospects for recovery and improve the quality of life of patients and their families. Advances in innovative, personalized therapies represent an important opportunity to further improve clinical outcomes in these patients.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"211-224"},"PeriodicalIF":4.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143363854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Weight Management for Fertility-Preservation Therapy in Endometrial Cancer: Opportunities and Challenges.

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-06 DOI: 10.1007/s11912-025-01635-9

XiaoDan Li, YiQian Chen, XiaoWei Li, Xiao Yang, Ling Zhou, Yuan Cheng, HongYi Hou, Dandan Yang, Yuanyuan Gong, Haihua Xiao, Jianliu Wang

{"title":"Weight Management for Fertility-Preservation Therapy in Endometrial Cancer: Opportunities and Challenges.","authors":"XiaoDan Li, YiQian Chen, XiaoWei Li, Xiao Yang, Ling Zhou, Yuan Cheng, HongYi Hou, Dandan Yang, Yuanyuan Gong, Haihua Xiao, Jianliu Wang","doi":"10.1007/s11912-025-01635-9","DOIUrl":"10.1007/s11912-025-01635-9","url":null,"abstract":"Purpose of review: Obesity is increasingly recognized as a significant factor impacting the outcomes of fertility-preserving therapies for endometrial cancer (EC). This review explores the effects of glycolipid metabolism on EC and its relationship with body weight. We will examine how excess body weight influences the effectiveness of fertility-preserving treatments and discuss potential mechanisms for effective weight management. Additionally, the review highlights the importance of comprehensive weight management as an adjunct strategy to enhance the efficacy of fertility-preserving interventions, providing insights into how to integrate metabolic health into clinical treatment protocols.Recent findings: Weight management can modify the tumor microenvironment by depriving the tumor of nutrients, whereas exercise can enhance immunity, potentially leading to tumor cell death. In addition, progesterone therapy may impede the proliferation of EC cells. Comprehensive weight management can serve as an essential adjuvant treatment for patients undergoing fertility-preserving therapies for EC. In this review, we highlight that comprehensive weight management can serve as a crucial adjuvant treatment for patients undergoing fertility-preserving therapies for endometrial cancer. Targeting glycolipid metabolism and addressing adiposity can improve hormonal balance, reduce inflammation, and enhance fertility outcomes. Further research is necessary to establish specific protocols and evaluate the effectiveness of these strategies in clinical practice.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"195-210"},"PeriodicalIF":4.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer.

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-20 DOI: 10.1007/s11912-025-01645-7

Shayan Smani, Julien DuBois, Kai Zhao, Ryan Sutherland, Syed N Rahman, Peter Humphrey, David Hesse, Wei Shen Tan, Darryl Martin, Soum D Lokeshwar, Fady Ghali

{"title":"Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer.","authors":"Shayan Smani, Julien DuBois, Kai Zhao, Ryan Sutherland, Syed N Rahman, Peter Humphrey, David Hesse, Wei Shen Tan, Darryl Martin, Soum D Lokeshwar, Fady Ghali","doi":"10.1007/s11912-025-01645-7","DOIUrl":"10.1007/s11912-025-01645-7","url":null,"abstract":"Purpose of review: This review examines the evolving landscape of non-muscle invasive bladder cancer (NMIBC) management, focusing on risk stratification, novel therapeutic strategies, and the integration of biomarkers into clinical care.Recent findings: Emerging genomic markers such as FGFR3 and TERT promoter mutations show promise for diagnosis and personalized treatment. Advances in immunotherapy, including the use of pembrolizumab and nadofaragene firadenovec, offer options for BCG-unresponsive NMIBC, though challenges like cost and adverse effects remain. Current guidelines emphasize stratified care based on risk, balancing treatment intensity with recurrence and progression risks. While transurethral resection with intravesical therapy remains the standard for most NMIBC, early radical cystectomy is pivotal for select high-risk cases. Future directions highlight the need for biomarker-driven models to refine treatment paradigms, reduce overtreatment, and improve long-term outcomes. Continued clinical trials are essential to validate these approaches and address unmet needs in NMIBC care.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"236-246"},"PeriodicalIF":4.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Defining The Role for Hormone Therapy in Biochemically Recurrent Prostate Cancer: What Counts as a Win for Patients? 确定激素疗法在生化复发性前列腺癌中的作用：怎样才能让患者获胜？

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-22 DOI: 10.1007/s11912-025-01647-5

Lauren O'Loughlin, Melissa L Abel, Ravi A Madan, David J Einstein

{"title":"Defining The Role for Hormone Therapy in Biochemically Recurrent Prostate Cancer: What Counts as a Win for Patients?","authors":"Lauren O'Loughlin, Melissa L Abel, Ravi A Madan, David J Einstein","doi":"10.1007/s11912-025-01647-5","DOIUrl":"10.1007/s11912-025-01647-5","url":null,"abstract":"Purpose of review: We evaluate unique clinical and drug development challenges in biochemically recurrent (BCR) prostate cancer. We examine risk stratification, critically appraise trials, and outline ongoing and future development of hormonal and non-hormonal options. We provide guidance for patient communication and examine how trial design may or may not reflect patient values.Recent findings: EMBARK established a potential role for enzalutamide with or without androgen deprivation therapy for certain patients with BCR, but questions remain about the study design and optimal usage. BCR is a heterogeneous condition with generally favorable long-term outcomes. Hormonal therapies are highly effective in suppressing-but not curing-micrometastatic disease, and are also highly effective when reserved for macrometastases, following surveillance. Ongoing studies are examining whether hormonal therapies add to metastasis-directed therapies and whether non-hormonal therapies may offer alternatives or combinations. Careful attention to trial design and endpoints will be essential for accurately measuring benefits and trade-offs.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"247-257"},"PeriodicalIF":4.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cell-free Tumor DNA: a Promising Technology for Diagnosis, Surveillance and Therapeutic Decision in Urothelial Carcinoma of the Bladder.

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-12 DOI: 10.1007/s11912-025-01648-4

Lucas Motta Martinez, Lorena Cristina São Leão Ribeiro, Rodrigo Gilles Guidi, Caio Mazzonetto Teofilo de Moraes, Catharina Ribeiro Lyra, Bruno Liebl, Vinicius Henrique Almeida Guimarães, Richard Dobrucki de Lima, Lucas Schenk de Almeida, Caio Vinicius Suartz, William Carlos Nahas, Leopoldo Alves Ribeiro-Filho

引用次数: 0